**Title:** Glial activation precedes alpha-synuclein pathology in a mouse model of Parkinson’s disease.

**Authors:** Maria Izco¹ PhD, F Javier Blesa² PhD, Guglielmo Verona³ PhD, J Mark Cooper⁴ PhD, Lydia Alvarez-Erviti¹ PhD

**Affiliations:**
¹ Laboratory of Molecular Neurobiology, Center for Biomedical Research of La Rioja (CIBIR), Piqueras 98, 3rd floor, 26006, Logroño, Spain.
² HM CINAC, Hospital Universitario HM Puerta del Sur, Av. Carlos V, 70, 28938 Móstoles, Madrid, Spain.
³ Wolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, UCL, Gower Street, London, United Kingdom
⁴ Department of Clinical Neuroscience, Institute of Neurology, UCL, Gower Street, London, UK.

* **Corresponding authors:** Lydia Alvarez-Erviti (laerviti@riojasalud.es)
  Maria Izco (mizco@riojasalud.es)
  Laboratory of Molecular Neurobiology
  Center for Biomedical Research of La Rioja (CIBIR)
  Piqueras 98, 3rd floor, 26006 Logroño (La Rioja)
  Telephone: +34 941 278 791

**Declarations of interest:** none

**Total number of pages:** 34

**Total number of figures:** 5

**Total number of tables:** 1
Abstract

Neuroinflammation is increasingly recognized as an important feature in the pathogenesis of Parkinson’s disease (PD). However, it remains unclear whether neuroinflammation contributes to nigral degeneration in PD or is merely a secondary marker of neurodegeneration. We aimed to investigate the temporal relationship between synucleopathy, neuroinflammation and nigrostriatal degeneration in a mouse model of PD. Mice received unilateral intrastriatal injection of alpha-synuclein pre-formed fibrils, alpha-synuclein monomer or vehicle and were sacrificed at 15, 30 and 90 days post-injection. Intrastriatal inoculation of alpha-synuclein fibrils led to significant alpha-synuclein aggregation in the substantia nigra peaking at 30 days after injection while the significant increase in Iba-1 cells, GFAP cells and IL-1β expression peaked earlier at 15 days. At 90 days, the striatal dopaminergic denervation was associated with astroglial activation. Alpha-synuclein monomer did not result in long-term glia activation or increase in inflammatory markers. The spread of alpha-synuclein aggregates into the cortex was not associated with any changes to neuroinflammatory markers. Our results demonstrate that in the substantia nigra glial activation is an early event that precedes alpha-synuclein inclusion formation, suggesting neuroinflammation could play an important early role in the pathogenesis of PD.

Keywords: Parkinson’s disease, mouse model, alpha-synuclein, neuroinflammation, microglia, astrocytes
Main text

Introduction

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder worldwide but effective disease modifying treatments are still awaited (Olanow et al., 2017). PD is characterized neuropathologically by the presence of intraneuronal Lewy bodies (LB) containing misfolded alpha-synuclein (α-syn), and the predominant loss of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc) leading to bradykinesia, tremor and postural instability (Fearnley et al., 1991).

While the primary cause of PD in the majority of the patients remains unknown, the rare genetic causes of PD have helped support several possible pathogenic mechanisms (Greenamyre et al., 2004; Lin and Beal, 2006; Schapira, 2006; Dick, 2012; Ebrahimi-Fakhari et al., 2012). The role of neuroinflammation and glial cell activation in PD has gained increased attention in recent years and are recognized as crucial features of PD pathogenesis, but it is unclear if they are drivers of disease progression and the selective loss of DA neurons. Genome wide association studies have found that polymorphisms in the HLA-DR (human MHCII) loci are associated with late-onset PD (Hamza et al., 2010). Indeed, pro-inflammatory cytokines are significantly elevated not only in plasma and cerebrospinal fluid (CSF) of PD patients but also in postmortem brain tissue (Mogi et al., 1994; Blum-Degen et al., 1995; Lindqvist et al., 2013). Animal studies have demonstrated progressive dopaminergic cell death and motor disabilities induced by sustained expression of different pro-inflammatory cytokines in the SNpc, which support the involvement of these pro-inflammatory cytokines in PD pathogenesis (Ferrari et al., 2006; De Lella-Ezcurra et al., 2010), and critically non-steroidal anti-inflammatory drugs have been shown to lower the risk of developing PD (Gagne et al., 2010; Manthripragada et al., 2011).

In the central nervous system (CNS), immune responses are mainly mediated by microglia and astrocytes. Microglial cells are the resident innate immune cells of the brain, which,
have a role in monitoring the brain for damage and invading pathogens. Upon changes in their surrounding environment, microglial cells activate, change their morphology ranging from hyper-ramified, hypertrophic or ameboid morphology and secrete different cytokines with functional consequences in the CNS. Since the first report showing activation of microglia in the SNpc of PD postmortem brains (McGeer et al., 1988), numerous studies have been published describing microglial changes in patients as well as in genetic and neurotoxic-based animal models of PD (McGeer et al., 2008; Long-Smith et al., 2009; Halliday and Stevens, 2011). Furthermore, the post-mortem data have been confirmed by in vivo positron emission tomography (PET) studies in PD patients, which also show a pronounced activation of microglia in the basal ganglia of PD brains in early and late stages of the disease (Gerhard et al., 2006; Bartels et al., 2010). Apart from microglial activation, numerous studies shows that astrocytes are activated in PD. Reactive astrogliosis characterized by the increased expression of glial fibrillary acidic protein (GFAP) have been reported in experimental PD animal models (Lee et al., 2010; Barcia et al., 2011) and in affected brain areas in PD patients (Yamada et al., 1992).

While these studies support a role for neuroinflammation in PD pathogenesis, its cause and temporal involvement has not yet been resolved. It remains unclear whether neuroinflammation contributes to nigral degeneration and disease progression in PD or is merely a secondary consequence of cell death. Recently, Luk et al. developed a progressive mouse model of PD based on the intrastriatal injection of alpha-synuclein pre-formed fibrils (α-syn PFF) into young wild type (WT) mice that recapitulates the time-dependent accumulation and propagation of LB-like α-syn pathology, death of nigrostriatal DA neurons and impairment of motor coordination (Luk et al., 2012). We have used this model to explore the temporal relationship between synucleinopathy, neuroinflammation and nigrostriatal degeneration. We observed microglia and astrocyte activation in SNpc prior to the development of α-syn pathology, suggesting that neuroinflammation precedes and potentially could drive dopaminergic dysfunction. These results implicate microglia and
astrocytes as important early mediators of PD pathogenesis and represent potential targets for early therapeutic interventions.

**Materials and methods**

- Preparation of mouse wild-type α-syn PFFs

Recombinant mouse wild-type α-syn was dissolved in sterile PBS (pH 7.4) and the concentration was carefully adjusted to 2 mg/ml (Abs 0.1% = 0.512). The protein was then left for one week at 37°C under agitation at 250 rpm. Fibrils were isolated by centrifugation at 10,600 g for 15 minutes. The total amount of fibrils formed was determined using a Jasco V-650 spectrophotometer by the difference between the total amount of protein in solution before incubation and the total amount of protein left in solution in the supernatant at the end of the incubation period. The pellet was then suspended at a concentration of 1 mg/ml in sterile PBS. A small aliquot was used to confirm the presence of genuine amyloid fibrils by Congo red staining. PFFs and soluble mouse α-syn were stored at –80 ºC. On the day of the surgery, α-syn PFFs were thawed and sonicated two cycles of 6 seconds 50 % power (10 microns amplitude) using a probe sonicator (Soniprep 150, MSE). A new aliquot of sonicated α-syn PFF was prepared every day of surgery. During the surgical procedure, α-syn PFFs were kept at room temperature while recombinant mouse wild-type α-syn monomer used for controls was kept at 4 ºC.

- Study design

Eight-to 9-week-old male C57BL6/C3H F1 mice were purchased from Charles River. All procedures involving animals were carried out in accordance with the European Communities Council Directive (2010/63/UE) and Spanish legislation (RD53/2013) on animal experiments and with approval from the ethical committee on animal welfare for our institution (Órgano Encargado del Bienestar Animal del Centro de Investigación Biomédica de La Rioja, OEBA-CIBIR). All efforts were made to minimize suffering and pain of the animals. Sample size was calculated using an online programme
All animals were randomly distributed to the cages by a technician of the animal facilities and before any procedure; the cages were randomized to each group by a person not involved in the study. All the experiments were blinded and the investigators responsible for data collection and analysis were blinded.

C57BL6/C3H F1 mice were deeply anesthetized with isoflurane and received two 2.5-μl injections of sonicated murine α-syn PFF (5 μg), α-syn monomer (5 μg) or PBS into the dorsal striatum (5 μl total; AP +0.2, ML -2.0, DV -3.4 and -2.6 from the skull) at a rate at 0.25 μl/min as previously described (Luk et al., 2012). Control animals were injected with an equal volume of sterile mouse α-syn monomer or PBS. After each injection, the needle was left in place for 5 min and then slowly withdrawn. Animals were monitored post-surgery and sacrificed at various time points 15, 30 and 90 days post injection (dpi) by overdose with isofluorane. For histological studies, brains were removed after transcardial perfusion while, for biochemical studies, brains were dissected and immediately frozen and stored at -80 °C until used.

- Behavioral assessment

To evaluate neuromuscular strength and motor coordination, the wire hang test was performed before intrastral injection and prior to sacrifice. Each mouse was placed on a wire lid of a conventional housing cage. The lid was lightly agitated to encourage the animal to grip the bars and then was turned upside down. The latency of mice to fall off the wire grid was measured and averaged over two trials (15 min apart). Trials were stopped if the mouse remained on the lid for over 15 min.

- Serum collection

For blood sampling, mice destined to biochemical studies were deeply anesthetized with an overdose of inhaled isofluorane and bled by cardiac puncture. Blood samples were collected in EDTA-free vials, allowed to clot at room temperature for four hours and stored
at 4 °C overnight. The samples were centrifuged at 1200 x g for 10 min to isolate serum and stored at -80 °C until processing.

- Multiplex determination of cytokines levels in serum

Serum levels of TNF-α, IFN-γ, IL-4, IL-5, IL-6 and IL-12/p70 were simultaneously determined using a multiplex immunoassay (ProcartaPlex™ Multiplex Immunoassays, Invitrogen™) according to the manufacturer’s instructions. The fluorescent signals were measured using a Luminex 100/200 reader (Luminex Corp., TX, USA) and were analyzed using a standard curve for each cytokine specified above, which were generated with a five-parameter logistic curve-fitting method. Cytokines that were below detection limit were assigned a value of zero in all analysis.

- Immunohistochemistry

Animals were transcardially perfused with PBS followed by 4 % paraformaldehyde in PBS. After carefully removing the brains from the skull, were post-fixed overnight in 4 % paraformaldehyde, cryoprotected in 30 % sucrose, rapidly frozen and stored at -80 °C until use. 30-μm-thick coronal sections were prepared using a cryostat. Slices were washed with PBS and were incubated with 3% hydrogen peroxidase in PBS to inactivate the endogenous peroxidase. The slices were washed in PBS and were incubated with a blocking solution (0.1 M PBS containing 5% NGS 0.04% Triton X-100) for 1 h. Slices were incubated 24/48 hour at 4ºC with the primary antibodies: anti-TH (Anti-Tyrosine Hydroxylase Antibody, clone 2/40/15, Chemicon®, Millipore, Cat# MAB5280, RRID: AB_2201526, dilution 1:2000), anti-alpha-synuclein (phospho S129) (Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)], Abcam, Cat# ab168381, RRID: AB_2728613, dilution 1:5000), anti-alpha-synuclein filament antibody (MJFR-14-6-4-2, conformation-specific, Abcam, Cat#ab209538, RRID: AB_2714215, dilution 1:40.000), anti-Iba1 (Anti-Iba1, Wako, Cat# 019-19741, RRID: AB_839504, dilution 1:500), anti-MHCII (MHC Class II (I-A/I-E) Monoclonal Antibody, Thermo Fisher Scientific, Cat# 14-5321-82, RRID: AB_467561,
dilution 1:500), anti-GFAP (Anti-Glial Fibrillary Acidic Protein antibody produced in rabbit, Sigma, Cat# G9269, RRID: AB_477035, dilution 1:2000). Slices were washed three times with PBS and were then incubated with fluorescent or biotinylated secondary antibody of the appropriate species. All the samples were processed simultaneously to obtain similar staining intensities.

The total number of TH-positive SNpc neurons was assessed by stereology in regularly spaced 30 μm-thick sections spanning the entire SNpc using StereoInvestigator software (MBF Bioscience). Striatal optical density (OD) of TH immunostaining was used as an index of the density of striatal dopaminergic innervation. Briefly, six representative rostro-caudal sections (at three levels of the striatum, bregma coordinates AP: +1.3, +0.5 and -0.4) were examined for each animal and regions of interest in the striatum were delineated and pixel densities were estimated using ImageJ. Background staining was quantified by measurement of pixel intensities in the white matter and subtracted from striatal regions for normalization.

For assessment of pathologic α-syn aggregates in the SNpc, 4 coronal sections (240 μm intervals between sections) for each animal were double labelled using antibodies against phospho S129 α-syn and TH to quantify intra-DA neuron alpha-synuclein inclusions. Numbers of S129 phospho-synuclein inclusions were manually quantified at 20x magnification from every eighth section (1:8 series) throughout the rostrocaudal axis of the SNpc. The data represent the total number of aggregates per section. Numbers of α-syn aggregates in the cortex and striatum were manually counted in 2 images (1 image from each hemisphere) for each section, with 3 representative sections (bregma coordinates AP: +1.3, +0.5 and -0.4) for each animal.

For evaluation of astroglial and microglial cells, sections were stained with GFAP, MHC class II and Iba1 antibodies. Iba1 and MHC class II staining was used to examine microglia activation while GFAP staining was used as an indicator of astrogliosis. Numbers of Iba1 and MHCII positive cells, as defined by those with darkly-stained cell bodies, were manually
counted at 20x magnification using digital photomicrographs. Estimation of the percentage of immunostained area by Iba1, MHC class II and GFAP positive cells was carried out using the threshold method of the ImageJ software (NIH). For the analyses of the SNpc, 4 coronal sections (240 μm intervals between sections, 1:8 series) for each animal and for each glial marker were included, whereas for the analyses of glial cells in the striatum and cortex, we included 3 selected representative rostro-caudal sections (bregma coordinates AP: +1.3, +0.5 and -0.4) for each animal and for each marker. Two images were taken at the same brain area of interest (1 image from each hemisphere) for each section. The Iba1 images in the brain regions examined were also qualitatively analyzed by using a 4 point categorical rating scale developed by Colburn and colleagues (Colburn et al., 1997), which provide an evaluation of microgliosis based on morphological and immunoreactivity changes, in a blinded fashion. The rating criteria and representative examples of each score are included in supplementary table 1.

- Quantitative PCR

Total RNA was isolated from frozen midbrain and cortical tissue samples using the RNeasy kit (Qiagen) according to the manufacturer's protocol. Subsequently, reverse transcription (RT) was performed with qSCRIP Reverse Transcriptase kit (Primer Design, Southampton, England) as per manufacturer's instruction. Transcripts obtained from the reverse transcriptase reaction were analyzed for IL-1β, TNF-α, IL-6 and IL-4 quantification by quantitative real-time PCR. qPCR experiments were performed on a StepOneTM Real-Time PCR system (Applied Biosystems) using Precision qPCR Mastermix (Applied Biosystems). The expression of each gene of interest was normalized by subtracting the cycle threshold (Ct) of β-actin from the gene of interest Ct (ΔCt). The 2−ΔΔCt method was then used to convert ΔCt values to mRNA fold changes relative to the control group at each time point. The primer sequences for mouse IL-1β (forward: 5’- TGCCACCTTTTGACAGTGAT-3’; reverse: 5’ GCTCTTGTTGATGTGCTGCT-3’), TNF-α (forward: 5’- ACGGCATGGATCTCAAAGAC-3’; reverse: 5’- GTGGGTGAGGAGCAGCAGT-3’), IL-6
(forward: ATGGATGCTACCAAACTGGAT; reverse: TGAAGGACTCTGGCTTTGTCT) and
IL-4 (forward: 5’- CCAAGGTGCTTGCATATT-3’; reverse: 5’-
ATCGAAAAGCCCGAAAGAGT-3’) were synthesized by Sigma and the sequence for
mouse actin (HK-SY-mo-600 against murine actin) was synthesized by Primer Design.

- Statistics

Data are presented as mean values ± the standard error of the mean (SEM). Statistical
analyses were carried out using R-commander software (version 2.2-1, R Core Team,
2013). Statistical comparisons between experimental groups at each time point were
performed with the parametric two-tailed Student’s t test or one-way ANOVA as indicated.
When variables were non-normally distributed, statistical differences were analyzed by non-
parametric Mann Whitney U test or Kruskal-Wallis followed by Dunns test. A probability
level of 0.05 or less was considered to be statistically significant.

Results

- Neuroinflammation precedes accumulation of α-syn aggregates in the SNpc after α-syn
PFF injection.

Thirty mice were injected in the striatum with α-syn PFF and were sacrificed at 15 (n=10),
30 (n=10) or 90 (n=10) dpi. We included as control groups at each time point (n=10) mice
injected with α-syn monomer or vehicle (PBS). In agreement with previous studies (Luk et
al., 2012; Tran et al., 2014), the injection of α-syn PFF in the striatum of normal mice
resulted in the progressive accumulation of phosphorylated α-syn inclusions in the SNpc. At
15 dpi sparse α-syn inclusions were observed in the SNpc, these increased significantly
peaking at 30 dpi (p=0.0162 in comparison to 15 dpi) before decreasing at 90 dpi (Fig 1a, b;
Sup Fig 1a). These α-syn inclusions were exclusively ipsilateral to the injection site at the
time points examined. Immunohistochemical analysis of midbrain sections stained with TH
and alpha-synuclein filament antibodies demonstrated the presence of oligomeric species of
α-synuclein in dopaminergic neurons in the ipsilateral SNpc of α-syn PFF injected mice at

10
15 dpi (Sup Fig 1b). Dopaminergic striatal innervation was only decreased in the posterior striatum after 90 dpi (p<0.001, Fig 1c, d) and the number of DA neurons in the SNpc after 90dpi was decreased by 15% compared to the contralateral after 90 dpi (not statistically significant, Fig 1e, f), leading to a significant impairment in the wire hanging test performance (p=0.025) (Sup Fig 1c). Intrastriatal injection of α-syn monomer did not result in the presence of α-syn aggregation or striatal dopaminergic denervation or loss of DA neurons in the SNpc (Sup Fig 2).

Coronal brain sections of PBS, α-syn monomer and α-syn PFF injected mice were examined immunohistochemically for the microglial (Iba1) and astroglial (GFAP) activation markers. Quantification of the number of Iba1 positive cells in the SNpc region of the ipsilateral side of the brain after intrastriatal α-syn PFF injection revealed a significant increase at 15 dpi (p<0.05), at 30 dpi (non-significant) and at 90 dpi (p<0.01; Fig 2a, b). The number of Iba1 positive cells in the ipsilateral SNpc of α-syn monomer injected mice remained unaltered and similar to control mice over time (Fig 2a, b). As expected, no differences in Iba1 staining were observed in the contralateral SNpc between control, α-syn monomer and α-syn PFF injected mice at any time point examined (Sup Fig 3a, b).

Morphological microglia alterations were detected at 15, 30 and 90 dpi (Fig 2a, insets in upper panel) in α-syn PFF injected mice, with microglia presenting a bushy appearance with swollen cell bodies and intensely stained, thickened and branched processes, characteristic of an activated phenotype. The qualitative analyses of microgliosis in the ipsilateral SNpc confirmed these changes in the microglial morphology. Whereas control mice displayed a low qualitative rating score over time (Fig 2c), α-syn PFF injected mice achieved a significant higher qualitative rating score at 15 and 90 dpi (p<0.01; Fig 2c) compared to control mice. Injection of α-syn monomer induced significant changes in the microglial morphology only at 15 dpi (p<0.01) and PBS injection did not result in any change in the number or morphology of microglial cells in the ipsilateral and contralateral SNpc (Fig 2a, b, c, Sup Fig 3a, b).
The increase in the number of Iba1-positive cells in the ipsilateral SNpc of α-syn PFF injected mice was confirmed by an increase in the area occupied by Iba1-positive cells at 15 and 30 dpi compared to control mice (15d: p<0.001; 30d: p<0.01; Sup Fig 3c). The change in the microglial morphology observed in α-syn monomer injected mice at 15 dpi was also confirmed by a mild increase in the area occupied by Iba1-positive cells at this time point (p<0.05 non-significant), whereas the area occupied by Iba-1 cells in the other time points was similar to control mice (Sup Fig 3c). In the control mice, the PBS injection did not significantly affect the area occupied by Iba1-positive cells in the ipsilateral SNpc over time (Sup Fig 3c) and no differences in Iba1 staining were observed in the contralateral SNpc between control, α-syn monomer and α-syn PFF injected mice at any time point examined (Sup Fig 3d).

We also quantified MHC class II immunoreactive microglia within the SNpc at 15, 30 and 90 dpi after PBS, α-syn monomer and α-syn PFF injection. An increase in the number of MHC class II positive microglial cells was observed in α-syn monomer and α-syn PFF injected mice 15 dpi compared to control mice (non-significant, Sup Fig 4a, b). However, although the number of microglial cells expressing MHC class II in α-syn PFF injected mice was decreased at 30 dpi, these cells remained significantly increased in α-syn monomer injected mice (p<0.05; Sup Fig 4a, b). No MHC class II positive microglial cells were observed at 90 dpi in mice from any experimental group (Sup Fig 4b) or in the contralateral SNpc at any time point (data not shown).

We investigated whether microglial activation in the ipsilateral SNpc of α-syn PFF injected mice was also accompanied by astrocyte activation. Intrastriatal α-syn PFF injection resulted in an increase in the area occupied by GFAP-positive cells in the ipsilateral SNpc at 15 and 30 dpi in comparison with control PBS-injected mice at each time point (15 dpi: p<0.05; 30 dpi: non-significant; Fig 2d, e). The area occupied by GFAP-positive cells in the ipsilateral SNpc of α-syn monomer injected mice was similar to control mice at all time points examined (Fig 2d, e). In the contralateral SNpc no GFAP-positive cells were
observed in control or α-syn monomer or α-syn PFF injected mice over time (data not shown).

We evaluated the mRNA expression of several inflammatory cytokines, IL-1β, TNF-α, IL-6 and IL-4, by qPCR in the ipsilateral SNpc of control, α-syn monomer and α-syn PFF injected mice at the various time points after injection. Interestingly, intrastratal injection of α-syn PFF induced an increase of IL-1β mRNA expression in the ipsilateral SNpc at all times examined (15 dpi: p=0.0159; 30 dpi: non-significant; 90dpi: p=0.0317; Fig 2f, Table 1) compared to corresponding control mice at each time point. The expression levels of TNF-α in the ipsilateral SNpc of PFF α-syn injected mice were increased at 90 dpi compared to control mice at this time point (p=0.0015). A similar profile as for TNF-α was observed for IL-6, although did not reach statistical significance (Fig 2f, Table 1). IL-4 expression levels were all similar to the control mice at each time point (Table 1). The expression levels of IL-1β, TNF-α, IL-6 and IL-4 remained unaltered in α-syn monomer injected mice at all time points examined (Sup Fig 5a).

- Striatal neuroinflammatory response correlates with dopaminergic denervation in the α-syn PFF mouse model

Striatal α-syn PFF injection resulted in a progressive accumulation of α-syn aggregates in the ipsilateral striatum at 30 and 90 dpi, with the greatest number of phosphorylated α-syn inclusions observed at 90 dpi time point (p=0.0091 compared to 30 dpi, Sup Fig 6a, b). α-syn aggregates were absent in α-syn monomer injected mice (data not shown). We examined the temporal neuroinflammatory response in the striatum of α-syn PFF and α-syn monomer injected mice. The ipsilateral striatum showed an increase in the number of Iba1 positive cells after 15 and 30 dpi for all α-syn monomer, α-syn PFF and PBS injections (Fig 3b). This was increased in comparison with the contralateral striatum for all experimental groups (Sup Fig 6c), consistent with changes due to the surgical procedure. This moderate microgliosis decreased with time in all experimental groups and no changes in Iba1 staining were observed 90 days after PBS, α-syn monomer or α-syn PFF injection compared to
contralateral striatum (Fig 3a, b, Sup Fig 6c). These results were confirmed by analyzing the area occupied by Iba1 positive cells (Sup Fig 6d, e). The qualitative analyses of microgliosis in the ipsilateral striatum of control, α-syn monomer and α-syn PFF injected mice did not revealed any significant difference between the experimental groups over time (Fig 3c). In the same way, microglial cells expressing MHC class II in the ipsilateral striatum were increased at early time points while decreased at 90 dpi, although no differences between the experimental groups were observed at any time point (Sup Fig 4c, d). We did not observe MHC class II positive microglial cells in the contralateral striatum of mice from any experimental group over time (data not shown).

A similar temporal pattern as described for microglia activation was observed in astroglia activation at early time points after striatal injection, with a marked increase in the area occupied by GFAP cells in the ipsilateral striatum at 15 dpi in PBS, α-syn monomer and α-syn PFF injected mice (Fig 3d), due to the surgical procedure. At 30 and 90 dpi, control and α-syn monomer mice showed further reduction in astroglia activation and no differences between ipsilateral and contralateral striatum were observed (contralateral data not shown). However, the area occupied by GFAP positive cells in the ipsilateral striatum of α-syn PFF injected mice remained significantly increased (90 dpi: p=0.0120, Fig 3d, e). This striatal astrogliosis observed at 30 and 90 dpi in α-syn PFF mice was accompanied by a significant increase in the expression levels of IL-1β compared to control mice at the same time point (30 dpi: p=0.0238; 90 dpi: p=0.0159, Fig 3f, Table 1). The expression levels of TNF-α and IL-6 also were increased at 90 dpi in α-syn PFF mice, although did not reach statistical significance. Injection of α-syn monomer did not result in changes in cytokine expression levels over time compared to control mice (Sup Fig 5b).

- α-syn aggregation does not directly drives neuroinflammation

To assess if inflammatory response is related to α-syn aggregation, we examined other areas distal to the injection site known to display moderate α-syn inclusions, such as somatosensory cortex (Luk et al., 2012; Sorretino et al., 2017). Accumulation of
phosphorylated α-syn inclusions were detected in the ipsilateral cortex at 30 and 90 days after intrastriatal α-syn PFF injection (Sup Fig 7a, b). Contralateral cortex developed scarce α-syn pathology 90 dpi and α-syn aggregates were absent in α-syn monomer injected mice (data not shown).

The number and the area occupied by iba1-positive cells in the ipsilateral cortex were similar between experimental groups (Fig 4a, b and Sup Fig 7d). As expected, we did not observe any difference in the number and in the area occupied by iba-1 positive cells in the contralateral cortex of control, α-syn monomer and α-syn PFF injected mice over time (Sup Fig 7c, e). The qualitative analysis of microgliosis did not revealed any difference in the morphology of microglial cells between the experimental groups over time (Fig 4c).

Although any difference was observed between the experimental groups at any time point, at 15 dpi we observed a slight increase in the area occupied by Iba1 cells and in the score of microglial morphology in the three experimental groups compared to 90 dpi, due to the surgical procedure. Immunohistochemical analysis of MHCII did not reveal any change in microglial MHCII expression in the cortex of mice from all experimental groups over time (data not shown) and the cytokines levels were also unaltered in the ipsilateral cortex of α-syn PFF mice over time compared to control mice at each time point (Table 1).

As described for striatum, an increase was observed in astroglia activation at early time points after striatal injection, with an increase in the area occupied by GFAP cells in the ipsilateral cortex at 15 and 30 dpi in control, α-syn monomer and α-syn PFF injected mice (Fig 4d, e), due to the surgical procedure. At 90 dpi, mice from all experimental groups showed further reduction in astroglia activation (Fig 4d, e).

- Instrastriatal α-syn PFF injection induces an increase in the serum levels of IL-6

Since some studies have demonstrated altered circulating levels of a series of cytokines in the serum of PD patients (Dobbs et al., 1999; Reale et al., 2009), we investigated whether intrastriatal α-syn PFF injection induced changes in the serum levels of specific cytokines.
Therefore, using multiplex immunoassays the levels of TNF-α, IFN-γ, IL-4, IL-5, IL-6 and IL-12p70 were determined in the serum of α-syn PFF and PBS injected mice at the 3 time points. Supplementary table 2 summarizes the mean (± standard error of the mean) values of cytokines expressed in pg/mL.

Since serum levels of cytokines in control mice did not vary over time (data not shown), all time points for the PBS injected mice were combined for comparison to α-syn PFF injected mice. Intrastriatal α-syn PFF injection resulted in a 3-fold increase in the serum level of IL-6 at 15 dpi (p=0.016) compared to control mice, with serum levels of IL-6 decreased at 30 and 90 dpi (Sup Table 1). However, the levels of the other cytokines did not differ significantly from the control mice at any time point (Sup Table 1).

Discussion

It is well documented that there is a close correlation between neuroinflammation and PD pathogenesis (McGeer et al., 2008; Halliday et al., 2011; Wang et al., 2015). However, a key question relates to whether neuroinflammation contributes to dopaminergic degeneration or is merely a secondary consequence of neuronal loss. Accrued evidence points to neuroinflammation acting as an active player in the α-syn-induced neurodegeneration. Studies to date in vitro (Beraud et al., 2013; Hoffmann et al., 2016) and in other α-syn based models of PD (Yamada et al., 2004; Theodore et al., 2008; Gao et al., 2011; Sanchez-Guajardo et al., 2010; Fischer et al., 2016; Thakur et al., 2017), support the idea that intracellular α-syn accumulation in the SNpc induces glial activation and release of inflammatory mediators, which mediate the loss of DA neurons. However, the supraphysiological α-syn levels or the α-syn species differences (human α-syn expressed in rat or mouse) limit the interpretation of the results. Recently, Duffy et al. investigated the temporal relationship of neuroinflammation in the rat model of synucleinopathy following intrastriatal injection of α-syn PFF, but they did not assess the neuroinflammatory response before α-syn inclusion formation (Duffy et al., 2018). We consider this information very
relevant to give new insights in the involvement of neuroinflammation in the pathogenesis of PD.

To investigate the time-course of glial activation prior to and following α-syn aggregation we used the α-syn PFF intrastriatal injected mouse model developed by Luk et al. (2012), which recapitulates the key pathological features of PD. Our data confirmed that intrastriatal injection of α-syn PFF led to intra-neuronal phosphorylated α-syn inclusions, loss of striatal dopaminergic innervation, selective loss of SNpc DA neurons and impaired motor coordination. The posterior part of the striatum showed a greater susceptibility to degenerate as previously described in other animal models and PD patients (Brooks et al., 2004; Blesa et al., 2012). The three time points evaluated reflect different stages of PD progression and represent a model to investigate whether microglial/astrocytes activation contributes to or is a consequence of α-syn aggregation and neuronal loss. The interpretation of our results is a variation to the previously proposed cascade of events (Gao et al., 2011; Duffy et al., 2018) as we propose the neuroinflammatory responses precede α-syn accumulation. However prolonged α-syn aggregation in the striatum appeared to correlate with decreased dopaminergic innervation and increased astrocytosis.

The increase in the number and the morphological changes of Iba1-positive cells in the ipsilateral SNpc of α-syn PFF injected mice 15 dpi is indicative of an early inflammatory response prior to significant α-syn accumulation. Our results are supported by data in PD patients implanted into the striatum with embryonic DA neurons (Olanow et al., 2019), which described inflammation and microglial activation in graft deposits long before the accumulation of α-syn pathology in implanted dopamine neurons. Moreover, it has been demonstrated in vivo that microglial depletion suppresses alpha-synuclein aggregation in alpha-synuclein PFF mice treated previously with PLX3397, an inhibitor of colony stimulating factor 1 receptor demonstrated to specifically deplete microglia (Guo et al., 2020). These observations support the hypothesis that microglial activation contributes to the development of α-syn pathology.
It is well documented that α-syn oligomers can induce an inflammatory response (Wilms et al., 2009; Kim et al., 2013; Fischer et al., 2016). The presence of alpha-synuclein oligomers and protofibrils in dopaminergic neurons at 15 dpi may be possible. These observations could explain our result that microglia activation precedes α-syn aggregation. However, the lack of changes in the number or morphology of Iba1-positive cells in the ipsilateral cortex, a region shown to display moderate α-syn inclusions, contradicts this relationship between α-syn pathology and microglia activation. It could be possible that other factors as rate of inclusion formation, achievement of certain brain region-dependent threshold in the number of neurons with α-syn pathology, local environment or glia density are involved in determining the microglial activation. In addition, single-cell transcriptomic analysis of microglia from discrete brain regions have revealed specific region-dependent subtypes of microglia (Grabert et al., 2016; Masuda et al., 2019), which could response to α-syn pathology in a different way. Nevertheless, our results suggest that microglial cells are activated as an early event in SNpc by a yet unknown mechanism. Future studies will be needed to investigate the trigger for microglia activation in the SNpc.

On other hand, microglial cells continue to be significantly activated at 90 dpi. Different signals given in the late time points from neurons with α-syn pathology could be involved in the late glial response, as release of α-syn from neurons or changes in neurotransmitter release or in proteins involved in the neuron-glia crosstalk (Fields et al., 2002; Liu et al., 2016). This glial activation is accompanied by the release of inflammatory cytokines. The increase in the expression levels of IL-1β and TNF-α in the SNpc at late time-point is in agreement with previous studies in PD brains and animal models (Mogi et al., 1994; Sriram et al., 2002; Wahner et al., 2007; Koprich et al., 2008). These studies concluded that both cytokines are toxic for the dopaminergic neurons of the SNpc, participating in the mechanism of cell death.

The activation of astrocytes also plays an important role in neuroinflammation (Colombo and Farina, 2016). Our results are in agreement with several studies demonstrating
astrogliosis in PD patients and animal models of PD (Kohutnicka et al., 1998; Miklossy et al., 2006; Booth et al., 2017; Yun et al., 2018). It has been suggested that astrocytic activation is induced by factors released by activated microglia, such as IL-1β and IL-6 (Woiciechowsky et al., 2004; Lin et al., 2006; Liddelow et al., 2017). Consequently, the acute microglia activation and the early increase in the IL-1β and IL-6 nigral levels could mediate astrocyte activation in the α-syn PFF injected mice. This result suggests a possible participation of astrocytes in the early neuroinflammatory response. The role of astrogliosis in PD has recently gained support from a study showing the prevention of conversion of astrocyte to an A1 neurotoxic phenotype is neuroprotective in animal models of PD (Yun et al., 2018).

Within the striatum, we did not observe microglial activation, suggesting that microglia activation in the striatum is not associated with α-syn accumulation, as reported previously by Duffy et al. 2018. However, interestingly, a significant astrogliosis was observed 90 dpi accompanied by a significant increase in the expression levels of IL-1β and IL-6. It has been described that the degeneration of the striatal dopaminergic innervation is followed by astrogliosis and that striatal astrocytes engulf dopaminergic debris in PD mouse models (Morales et al., 2016; Morales et al., 2017). Nevertheless, it could be possible that astrocytes participate in the process of degeneration of striatal dopaminergic terminals.

The intrastriatal injection of α-syn monomer only resulted in changes in the morphology of microglial cells in the ipsilateral SNpc, accompanied by an increase in the number of microglia cells expressing MHC class II. A previous study showed that non-aggregated WT synthetic α-syn induces an acute inflammatory response in vitro and in vivo 24 hours following intranigral injection (Couch et al., 2011). Our results would suggest an early microglial response to extracellular monomeric α-syn, possibly involving the engulfment or clearing of extracellular α-syn released from DA neurons by microglial cells for antigenic presentation in the context of MHC class II. This is in accordance with previous studies
demonstrating that extracellular monomeric \( \alpha \)-syn enhance microglial phagocytosis (Park et al., 2008).

On the other hand, immune activation in PD is not restricted to brain sites and changes in the peripheral blood levels of some cytokines, including IL-6, have been reported by several authors (Dobbs et al., 1999; Reale et al., 2009; Scalzo et al., 2010; Pereira et al., 2016), as we observed in the \( \alpha \)-syn injected mice at early time points. In addition, our results agree with a very recent study that have demonstrated that \( \alpha \)-syn pathology in the CNS is sufficient to induce monocyte dysregulation in the periphery of a transgenic mouse model of PD (Grozdanov et al., 2019). All these data highlight the potential relation of the peripheral deregulation in the cytokine network with the neuroinflammatory process in PD.

**Conclusions**

In conclusion, although detailed mechanisms remain to be defined, we provide in vivo evidence that neuroinflammatory response precedes \( \alpha \)-syn inclusion formation and is restricted to nigrostriatal area of \( \alpha \)-syn PFF injected mice. Fig 5 summarizes the time course of synucleinopathy, neuroinflammation and degeneration in the SNpc (left graph) and striatum (right graph) following intrastrial \( \alpha \)-syn PFF injection. Our data adds novel insights into the mechanisms responsible for the etiology of PD and further identifies potential pathway for therapeutic intervention.
List of abbreviations

CNS: Central Nervous System
CSF: Cerebrospinal fluid
DA: Dopamine
dpi: days post-injection
GFAP: glial fibrillary acidic protein
LB: Lewy bodies
OD: Optical densitometry
PET: Positron emission tomography
PD: Parkinson’s disease
SEM: standard error of the mean
SNpc: Substantia nigra pars compacta
TH: Tyrosine hydroxylase
WT: Wild type
α-syn PFF: alpha-synuclein pre-formed fibrils
α-syn: alpha-synuclein
Declarations

Ethics approval and consent to participate: All procedures involving animals were carried out in accordance with the European Communities Council Directive (2010/63/UE) and Spanish legislation (RD53/2013) on animal experiments and with approval from the ethical committee on animal welfare for our institution (Órgano Encargado del Bienestar Animal del Centro de Investigación Biomédica de La Rioja, OEB-A-CIBIR).

Consent for publication: Not applicable.

Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests.

Funding: This study was funded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovacion y Universidades (CP1500200). Co-funded by European Regional Development Fund (FEDER) "A way to make Europe".

Authors’ contributions: M.I. and L.A.E. designed the study. L.A.E. performed qPCR for analysis of expression levels of cytokines. M.I. performed alpha-synuclein PFFs mouse experiments and immunohistochemical analysis. F.J.B. performed stereological analysis. G.V. synthetized and prepared alpha-synuclein PFFs. M.I., J.M.C. and L.A.E. wrote the manuscript. All authors contributed to the manuscript and its amendments.

Acknowledgements: Not applicable.

Submission declaration: The work has not been published elsewhere and is not under review with another journal. All authors have read and approved the manuscript.
References


Sriram, K., Matheson, J.M., Benkovic, S.A., Miller, D.B., Luster, M.I., O’Callaghan, J.P., 2002. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity:


**Figure captions**

**Figure 1: Analysis of α-syn aggregation and DA neurons in SNpc and striatal dopaminergic innervation in the α-syn PFF mouse model.** a) Representative images of intraneuronal phospho-α-syn inclusions in the ipsilateral SNpc of α-syn PFF and PBS (Control) injected mice at various dpi. Scale bars represent 200 μm (top panels) and 50 μm (low panels) b) Quantification of Ser129 phospho-α-syn positive aggregates in the ipsilateral SNpc at 15, 30 and 90 dpi. Data are expressed as mean ± SEM (n=4-8). *p<0.01 different from PFF 15d, non-parametric Mann Whitney U test. c) Photomicrographs of striatal sections showing TH immunolabeling of mice at 15, 30 and 90 dpi or at 90 dpi after control (PBS) injection. d) Optical density quantification of ipsilateral striatal TH normalized to the contralateral striatum. Data are expressed as mean ± SEM (n=4-8). ***p<0.001 compared to Control group, parametric Student’s t-test. e) TH staining of dopaminergic neurons in a coronal section of the midbrain in α-syn PFF and Control injected mice at increasing dpi. Scale bar represents 500 μm. Arrow points to the decrease in the number of DA neurons. f) Unbiased stereologic quantification of TH-immunoreactive neurons in ipsilateral and contralateral SNpc of mice injected with α-syn PFF or Control (PBS) at increasing dpi. Data are expressed as mean ± SEM (n=4-8).

**Figure 2: Glial cell activation in the SNpc of α-syn PFF injected mice.** a) Representative images of ipsilateral SNpc sections immunolabeled with Iba1 microglial marker from Control (PBS), α-syn monomer and α-syn PFF injected mice at increasing dpi. Scale bar represents 50 μm. Insets show images at higher magnification (scale bar 10 μm). b) Quantification of the number of Iba1-positive cells in the ipsilateral SNpc of Control (PBS), α-syn monomer and α-syn PFF injected mice with increasing dpi. Data are expressed as mean ± SEM (n=4-8). *p<0.05, **p<0.01 compared to control at same time point, ΔΔp<0.01 compared to Monomer, one-way ANOVA. c) Qualitative rating of microgliosis in the ipsilateral SNpc revealed by Iba1 immunohistochemistry using a 4 point scale ranging from 0 (no microgliosis) to 3 (pronounced microgliosis) according to microglia...
morphology. Values are expressed as mean ± SEM (n= 4-8). **p<0.01 compared to control, Δp<0.05 compared to Monomer, one-way ANOVA. d) Representative images of ipsilateral SNpc double immunostained against TH (in red) and GFAP (in green) of Control (PBS), α-syn monomer and α-syn PFF injected mice. Scale bars: 40 μm. e) Analysis of the area occupied by GFAP-positive cells in the ipsilateral SNpc of control, α-syn monomer and α-syn PFF injected mice. Data are expressed as mean ± SEM (n= 4-8). *p<0.05 compared to control, Δp<0.05 compared to Monomer, one-way ANOVA. f) Fold changes in IL-1β, TNF-α and IL-6 mRNA levels in the ipsilateral midbrain of α-syn PFF injected mice at 15, 30 and 90 dpi. Fold changes were relative to the control group at each time point. The control group value at each time point is set at 1.0 as indicated by the dashed line. Data are expressed as mean ± SEM (n=4). Non-parametric Mann Whitney U test, statistical analyses compared to control group at each time point, *p<0.05, **p<0.01.

Figure 3: Neuroinflammatory response in the striatum. a) Representative images of ipsilateral striatal sections immunolabeled with Iba1 microglial marker in control, α-syn monomer and α-syn PFF injected mice at 90 dpi. Scale bar represents 50 μm. b) Quantification of the number of Iba1-positive cells in the ipsilateral striatum of Control (PBS), α-syn monomer and α-syn PFF injected mice. Data are expressed as mean ± SEM (n= 4-8). c) Qualitative rating of ipsilateral striatal microgliosis revealed by Iba1 immunohistochemistry using a 4 point scale ranging from 0 (no microgliosis) to 3 (pronounced microgliosis) according to microglia morphology. Data are expressed as mean ± SEM (n= 4-8). d) Analysis of the area occupied by GFAP positive cells in the ipsilateral striatum of Control (PBS), α-syn monomer and α-syn PFF injected mice with increasing dpi. Data are expressed as mean ± SEM (n= 4-8). *p<0.05 compared to control, one-way ANOVA. e) Representative images of ipsilateral striatum immunostained against GFAP (green) of Control (PBS), α-syn monomer and α-syn PFF injected mice at 90 dpi. Scale bar represents 50 μm. f) Fold changes in IL-1β, TNF-α and IL-6 mRNA levels in the ipsilateral striatum of α-syn PFF injected mice at 15, 30 and 90 dpi. Fold changes were relative to the
control group at each time point. The control group value at each time point is set at 1.0 as indicated by the dashed line. Data are expressed as mean ± SEM (n=4-8). Non-parametric Mann Whitney U test, statistical analyses compared to control group at each time point, *p<0.05.

**Figure 4: Analysis of glial cell activation in the cortex.** a) Representative images of ipsilateral cortical sections immunolabeled with Iba1 microglial marker in Control (PBS), α-syn monomer and α-syn PFF injected mice 15, 30 and 90 dpi. Scale bar represents 50 μm. Insets show images at higher magnification (scale bar 10 μm). b) Quantification of the number of Iba1-positive cells in the ipsilateral cortex of Control (PBS), α-syn monomer and α-syn PFF injected mice. c) Qualitative rating of ipsilateral cortical microgliosis revealed by Iba1 immunohistochemistry using a 4 point scale ranging from 0 (no microgliosis) to 3 (pronounced microgliosis) according to microglia morphology. d) Quantified percentage of area occupied by GFAP-positive cells in the ipsilateral cortex of Control (PBS), α-syn monomer and α-syn PFF injected mice. e) Representative images of ipsilateral cortical sections labeled for GFAP immunoreactive astroglia from control, α-syn monomer and α-syn PFF injected mice. Scale bar represents 40 μm. Data are expressed as mean ± SEM (n=4-8). One-way ANOVA, statistical analyses compared to control group at each time point.

**Figure 5: Time course of α-syn aggregation, neuroinflammation and neurodegeneration in the nigrostriatal area of the α-syn PFF mouse model.** The figure summarizes the main temporal changes that occur in the SNpc (left graph) and striatum (right graph) following striatal α-syn PFF injection. Data represent the percentage of change relative to control at each time point.
a) Images showing different time points: Control, 15d, 30d, 50d.

b) Graph showing the number of TUNEL-positive cells over days post injection.

c) Graph showing the qualitative rating score of microglia over days post injection.

d) Images showing immunofluorescence at different time points: Control 15d, PFF 15d, PFF 30d, PFF 90d, Control 90d, Monomer 15d, Monomer 30d, Monomer 90d.

e) Graph showing the percentage area occupied by GATA cells over days post injection.

f) Graph showing the expression of IL-1β, TNF-α, and IL-6 over days post injection.
Table 1: qRT-PCR analysis for mRNA levels of cytokines in ipsilateral midbrain, cortex and striatum of control and α-syn PFF mice over time. The results are expressed as average fold change relative to the controls ± SEM, n=5 in each group. Non-parametric Kruskal-Wallis test, statistical analyses compared to control group, *p<0.05, **p<0.01.

<table>
<thead>
<tr>
<th>Cytokine (Fold mRNA)</th>
<th>Control</th>
<th>PFF 15d</th>
<th>PFF 30d</th>
<th>PFF 90d</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Midbrain</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-1β</td>
<td>1,00 ± 0,20</td>
<td>2,57 ± 0,70 *</td>
<td>2,59 ± 0,10</td>
<td>2,62 ± 0,91 *</td>
</tr>
<tr>
<td>IL-6</td>
<td>1,00 ± 0,15</td>
<td>1,44 ± 0,33</td>
<td>1,10 ± 0,19</td>
<td>2,25 ± 0,56</td>
</tr>
<tr>
<td>TNF-α</td>
<td>1,00 ± 0,33</td>
<td>1,86 ± 0,44</td>
<td>0,69 ± 0,11</td>
<td>2,44 ± 0,61**</td>
</tr>
<tr>
<td>IL-4</td>
<td>1,00 ± 0,20</td>
<td>0,90 ± 0,17</td>
<td>0,87 ± 0,13</td>
<td>0,82 ± 0,12</td>
</tr>
<tr>
<td><strong>Striatum</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-1β</td>
<td>1,00 ± 0,20</td>
<td>1,88 ± 0,38</td>
<td>3,21 ± 0,82 *</td>
<td>3,17 ± 0,94*</td>
</tr>
<tr>
<td>IL-6</td>
<td>1,00 ± 0,19</td>
<td>1,81 ± 0,37</td>
<td>1,48 ± 0,21</td>
<td>1,96 ± 0,46</td>
</tr>
<tr>
<td>TNF-α</td>
<td>1,00 ± 0,14</td>
<td>2,92 ± 0,52 *</td>
<td>0,81 ± 0,21</td>
<td>2,33 ± 0,93</td>
</tr>
<tr>
<td>IL-4</td>
<td>1,00 ± 0,27</td>
<td>1,48 ± 0,35</td>
<td>0,64 ± 0,17</td>
<td>1,72 ± 0,63</td>
</tr>
<tr>
<td><strong>Cortex</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-1β</td>
<td>1,00 ± 0,12</td>
<td>1,31 ± 0,36</td>
<td>1,71 ± 0,19</td>
<td>1,87 ± 0,29</td>
</tr>
<tr>
<td>IL-6</td>
<td>1,00 ± 0,16</td>
<td>1,18 ± 0,34</td>
<td>1,35 ± 0,21</td>
<td>1,53 ± 0,22</td>
</tr>
<tr>
<td>TNF-α</td>
<td>1,00 ± 0,28</td>
<td>1,15 ± 0,17</td>
<td>1,28 ± 0,08</td>
<td>1,44 ± 0,18</td>
</tr>
<tr>
<td>IL-4</td>
<td>1,00 ± 0,18</td>
<td>1,16 ± 0,16</td>
<td>1,42 ± 0,30</td>
<td>1,63 ± 0,21</td>
</tr>
</tbody>
</table>